Volume 24, Number 7—July 2018
Research
Registry Cohort Study to Determine Risk for Multiple Sclerosis after Vaccination for Pandemic Influenza A(H1N1) with Arepanrix, Manitoba, Canada
Table 1
Cohort characteristics by vaccination status, Manitoba, Canada, 2009–2012*
Variable | No. (%) persons |
||||||
---|---|---|---|---|---|---|---|
Adjuvanted A(H1N1)pdm09 |
Unadjuvanted A(H1N1)pdm09 |
TIV alone | Unvaccinated | ||||
Alone | And TIV | Alone | And TIV | ||||
Total |
267,539 (100) |
61,239 (100) |
10,592 (100) |
1,977 (100) |
144,594 (100) |
485,941 (100) |
|
Age group, y | |||||||
<14 | 83,097 (31.1) | 10,206 (16.7) | 1,245 (11.8) | 109 (5.5) | 4,915 (3.4) | 99,463 (20.5) | |
15–34 | 62,261 (23.3) | 12,637 (20.6) | 4,717 (44.5) | 679 (34.3) | 7,094 (4.9) | 92,008 (18.9) | |
35–44 | 38,401 (14.4) | 9,272 (15.1) | 1,835 (17.3) | 363 (18.4) | 6,463 (4.5) | 51,795 (10.7) | |
45–54 | 39,958 (14.9) | 12,018 (19.6) | 1,452 (13.7) | 389 (19.7) | 12,696 (8.8) | 74,454 (15.3) | |
>55 |
43,822 (16.4) |
17,106 (27.9) |
1,343 (12.7) |
437 (22.1) |
113,426 (78.4) |
168,221 (34.6) |
|
Sex | |||||||
F |
144,461 (54.0) |
31,081 (50.8) |
7,352 (69.4) |
1,194 (60.4) |
82,868 (57.3) |
266,956 (54.9) |
|
Urban residence |
146,256 (54.7) |
41,916 (68.4) |
6,202 (58.6) |
1,604 (81.1) |
96,605 (66.8) |
292,583 (60.2) |
|
Income quintile | |||||||
Q1 (lowest) | 53,269 (19.9) | 9,766 (15.9) | 1,803 (17.0) | 279 (14.1) | 27,899 (19.3) | 92,147 (19.0) | |
Q2 | 47,036 (17.6) | 11,066 (18.1) | 1,833 (17.3) | 355 (18.0) | 27,593 (19.1) | 91,214 (18.8) | |
Q3 | 48,257 (18.0) | 10,976 (17.9) | 1,766 (16.7) | 358 (18.1) | 28,037 (19.4) | 91,542 (18.8) | |
Q4 | 50,592 (18.9) | 12,454 (20.3) | 2,373 (22.4) | 447 (22.6) | 27,167 (18.8) | 95,379 (19.6) | |
Q5 (highest) | 62,320 (23.3) | 15,602 (25.5) | 2,613 (24.7) | 503 (25.4) | 25,103 (17.4) | 101,411 (20.9) | |
Cannot be calculated |
6,065 (2.3) |
1,375 (2.2) |
204 (1.9) |
35 (1.8) |
8,795 (6.1) |
14,248 (2.9) |
|
Immunosuppressed | 11,541 (4.3) | 4,028 (6.6) | 322 (3.0) | 78 (3.9) | 20,990 (14.5) | 33,561 (6.9) | |
Autoimmune diseases | 6,680 (2.5) | 2,669 (4.4) | 197 (1.9) | 45 (2.3) | 10,179 (7.0) | 17,661 (3.6) | |
Any chronic diseases | 18486 (6.9) | 7,485 (12.2) | 364 (3.4) | 96 (4.9) | 42,909 (29.7) | 65,158 (13.4) | |
Pregnant, % of all 15–49-year-old females |
2,184 (3.1) |
355 (2.4) |
2,857 (50.6) |
330 (40.4) |
816 (7.4) |
5,160 (4.9) |
|
High priority for A(H1N1)pdm09 vaccine | 142,909 (53.4) | 25,652 (41.9) | 6,200 (58.5) | 683 (34.5) | 59,165 (40.9) | 230,948 (47.5) | |
High priority for TIV | 42,207 (15.8) | 12,958 (21.2) | 3,231 (30.5) | 419 (21.2) | 105,557 (73.0) | 158,565 (32.6) | |
Received 2008–09 TIV | 41,896 (15.7) | 22,231 (36.3) | 1,237 (11.7) | 542 (27.4) | 109,107 (75.5) | 42,071 (8.7) | |
Received pneumococcal vaccine | 49,203 (18.4) | 11,554 (18.9) | 286 (2.7) | 64 (3.2) | 87,552 (60.6) | 86,261 (17.8) |
*A(H1N1)pdm09, pandemic influenza A(H1N1) strain; Q, quintile; TIV, trivalent influenza vaccine.